z-logo
open-access-imgOpen Access
INHIBITION OF UREASE ENZYME ACTIVITY BY UREA AND THIOUREA DERIVATIVES OF DIPEPTIDES CONJUGATED 2, 3-DICHLOROPHENYL PIPERAZINE
Author(s) -
D. M. Suyoga Vardhan,
H. K. Kumara,
H. Pavan Kumar,
D. Channe Gowda
Publication year - 2017
Publication title -
international journal of pharmacy and pharmaceutical sciences/international journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2656-0097
pISSN - 0975-1491
DOI - 10.22159/ijpps.2017v9i9.19425
Subject(s) - thiourea , piperazine , chemistry , urease , urea , conjugated system , enzyme , carbodiimide , trifluoroacetic acid , organic chemistry , stereochemistry , polymer
Objective: Studies on enzyme inhibition remain an important area of pharmaceutical research since these studies have led to the discoveries of drugs used in a variety of physiological conditions. In search of novel urease enzyme inhibitors, four dipeptides were synthesized, conjugated to 2,3-dichlorophenyl piperazine analogue and converted into urea/thiourea derivatives.Methods: The peptides were synthesized by solution phase method and conjugated to 2,3-dichlorophenyl piperazine (PZN) using 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide (EDCI)/hydroxybenzotriazole (HOBt) as a coupling agent and N-methylmorpholine (NMM) as a base. The tert-butyloxycarbonyl (Boc) group was removed using trifluoroacetic acid (TFA), neutralized with NMM and converted to urea and thiourea derivatives using substituted phenyl isocyanates and isothiocyanates respectively.Results: Most of the synthesized analogues were found to be good inhibitors of urease enzyme activity. The conjugates of thiourea with F and Cl substituents at meta or para positions showed predominant urease inhibitory activity. The analogue 23 was nearly 10 fold (2 µM) more potent than the reference standard, 21.0±0.11 µM.Conclusion: The reported activity was correlated with some of the literature reported urease inhibitors and found that our compound 23 was more potent than the existing ones.  

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here